(Press-News.org) HOUSTON - Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.
"Our research indicates when the two drugs were used at the same time, Herceptin was less effective," said study senior author Zhen Fan, M.D., associate professor in MD Anderson's Department of Experimental Therapeutics.
Natural erythropoietin (EPO) controls the body's red blood cell production. Manufactured versions called erythropoietin-stimulating agents or recombinant erythropoietin treat anemia caused by kidney failure and cancer treatment.
"Recombinant erythropoietin is a great drug, and it's saved many lives," Fan said. "Some studies, however, have shown that the drug has effects on cancer cells. We wanted to see if recombinant erythropoietin thwarts Herceptin, based on our understanding of how the two drugs work."
The researchers tested their hypothesis using breast cancer mouse models, then followed up with laboratory experiments on cancer cell lines to work out the molecular details. A retrospective case control study of 111 breast cancer patients supported their findings from the mouse studies.
Human epidermal growth factor receptor-2 (HER2) is overexpressed in 25-30 percent of breast cancers. The drug trastuzumab, known commercially as Herceptin, is an antibody designed to block HER2. Because resistance develops, only about a third of HER2-positive patients respond to the drug.
The presence of functional erythropoietin receptors on HER2-positive breast cancer could be one resistance mechanism, Fan said.
"The whole idea with targeted therapy against the HER2 protein is to shut off the downstream molecular activity launched by HER2," Fan said. "Erythropoietin can activate similar downstream pathways if its receptor is expressed on cancer cells, causing antagonism between the two drugs."
Fan and colleagues demonstrate that when erythropoietin connects with its receptor protein (EpoR), it launches a chain of events that activates Src, a crucial component of a pathway that trastuzumab blocks. It also shuts down a well-known tumor-suppressing gene called PTEN that is believed to be important to trastuzumab's activity against cancer cells.
There is controversy in academic circles about the role and function of EpoR in cancer cells and other types of cells not involved in blood production. It's important to note, Fan said, the team found no evidence that recombinant erythropoietin alone promotes cancer growth.
Tracking down the details
In three HER2-positive breast cancer cell lines, trastuzumab inhibited cell survival and proliferation, while recombinant erythropoietin stimulated cell survival and growth. When the three lines were treated together with trastuzumab and the anemia drug, cell survival increased from 58 percent to 80 percent, 57 percent to 77 percent, and 34 percent to 57.5 percent, respectively.
Two HER2-positive breast cancer cell types were introduced to mice, who then either received mock treatment, trastuzumab only, erythropoietin only or both drugs. Tumors treated with trastuzumab either shrank or stopped growing, with average tumor volume close to zero after 50 days in one cell line and barely registering in another. Growth of tumors treated with erythropoietin closely tracked the control group, increasing rapidly to an average volume of 1,500 cubic millimeters in one line and 600 mm3 in another. Tumors treated with both drugs grew more slowly to about 700 mm3 and 300 mm3.
Improved patient survival in small study
In a retrospective case-control study of patients with HER2-positive breast cancer that had spread, the team compared overall survival and progression-free survival between a group of 37 patients who received trastuzumab plus chemotherapy and recombinant erythropoietin to a matched control group of 74 whose cancer was treated the same way but who received no EPO.
A statistically significant difference in progression-free survival emerged at one year, with 40 percent of the control group having stable disease compared with 19 percent of the erythropoietin group. Overall progression-free survival differences across two years were not statistically significant.
The control group also had better overall survival than the erythropoietin group that was statistically significant in an analysis of multiple variables.
Fan emphasized that clinical findings should be interpreted with caution because the study was small and retrospective. Patients who received erythropoietin might have been sicker than the patients not treated with erythropoietin. Their findings need to be confirmed by larger clinical studies.
"We're expanding this study to include other types of cancer," Fan said. "Of course, different types of cancers are treated with different types of targeted therapies. We need to design our studies using different targeting agents than Herceptin to study whether erythropoietin can antagonize these drugs," Fan said.
Looking forward, Fan said, researchers need to find out why and how some cancer cells express the receptor protein for erythropoietin, and to what extent cancer cells express EpoR. "Recombinant erythropoietin helps to improve a patient's general condition without the need for a blood transfusion," Fan said. "If we can figure out how the expression of the erythropoietin receptor is regulated in cancer cells, we may come up with some new strategies to allow cancer patients to receive the drug for their anemia and fatigue without compromising their treatment with novel targeted therapies, such as anti-HER2 therapy with Herceptin."
INFORMATION:
The study was funded by a grant from the National Cancer Institute, research awards by the Breast Cancer Research Foundation, and by MD Anderson's Cancer Center Support Grant from from the NCI.
Co-authors with Fan, all from MD Anderson, are first author Ke Liang, Yang Lu, Xinqun Li, M.D., Ph.D., and John Mendelsohn, M.D., all of the department of Experimental Therapeutics; Francisco Esteva, M.D., Ph.D., Giampaolo Bianchini, M.D., Ching-Yi Yang and Gabriel Hortobagyi, M.D., all of the Department of Breast Medical Oncology; Yong Li, Ph.D., Constance Albarracin, M.D., Ph.D., of the Department of Pathology; Katherine Stemke-Hale, Ph.D., and Gordon Mills, M.D., Ph.D., of the Department of Systems Biology; and Chun-Te Chen and Mien-Chie Hung, M.D., Ph.D., of the Department of Molecular and Cellular Oncology.
Erythropoietin counteracts breast cancer treatment with herceptin
Researchers find erythropoiesis-stimulating drugs cut response to HER2 targeted therapy
2010-11-16
ELSE PRESS RELEASES FROM THIS DATE:
Stem cell patch may result in improved function following heart attack
2010-11-16
CINCINNATI—University of Cincinnati (UC) researchers have found that applying a stem cell-infused patch together with overexpression of a specific cell instruction molecule promoted cell migration to damaged cardiac tissue following heart attack and resulted in improved function in animal models.
The researchers also found that function improved more so than when stem cells were directly injected in heart tissue—a therapy that is being studied elsewhere.
These findings are being presented for the first time at the American Heart Association's Scientific Meeting in Chicago ...
Shortest-pulse X-ray beams could illuminate atomic, molecular interactions
2010-11-16
ANN ARBOR, Mich.---Ultra-short X-ray beams produced at the University of Michigan could one day serve as more sensitive medical diagnostic tools, and they could work like strobe lights to allow researchers to observe chemical reactions that happen in quadrillionths of a second.
The researchers used the HERCULES high-intensity, table-top laser to create X-ray beams that rival those made in expensive and massive synchrotron particle accelerators. The National Synchrotron Light Source II, for example, under construction at Brookhaven National Laboratory, is slated to be ...
Novel ocean-crust mechanism could affect world's carbon budget
2010-11-16
The Earth is constantly manufacturing new crust, spewing molten magma up along undersea ridges at the boundaries of tectonic plates. The process is critical to the planet's metabolism, including the cycle of underwater life and the delicate balance of carbon in the ocean and atmosphere.
Now, scientists at the Woods Hole Oceanographic Institution (WHOI) have observed ocean crust forming in an entirely unexpected way—one that may influence those cycles of life and carbon and, in turn, affect the much-discussed future of the world's climate.
Working at the Guaymas basin ...
Researchers 'grow Rett syndrome' in a Petri dish
2010-11-16
(Cincinnati, OH) – A groundbreaking study published Friday in the leading scientific journal, Cell, revealed that a team of investigators had successfully generated nerve cells using skin cells from four individuals with Rett syndrome. The study, funded in part by IRSF, was led by Dr. Alysson Muotri at the University of California, San Diego--a leading researcher in the stem cell field.
The article, titled 'A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells,' describes how the team used a newly-devised procedure ...
Research examines key qualities that voters expect in their presidential candidates
2010-11-16
What are the key characteristics that voters consider when they're choosing their candidate for president? New research led by Judith Trent, a professor of communication at the University of Cincinnati, yields some surprising findings from surveys from the 2008 primary campaign in New Hampshire – a historic campaign in itself because of the diverse demographic characteristics of some of the leading contenders. The top ideal quality picks are a candidate's honesty and willingness to talk about the challenges affecting the nation.
The article, titled, "Cracked and Shattered ...
More evidence that melanoma does not conform to the cancer stem cell model
2010-11-16
ANN ARBOR, Mich---University of Michigan researchers have determined that most types of melanoma cells can form malignant tumors, providing new evidence that the deadliest form of skin cancer does not conform to the increasingly popular cancer stem cell model.
In addition, the researchers found that melanoma tumor cells can change their appearance by switching various genes on and off, making the malignant cells a stealthy, shape-shifting target for researchers seeking new treatments, according to a team led by Sean Morrison, director of the U-M Center for Stem Cell Biology.
Both ...
Change in temperature uncovers genetic cross talk in plant immunity
2010-11-16
Like us, plants rely on an immune system to fight off disease. Proteins that scout out malicious bacterial invaders in the cell and communicate their presence to the nucleus are important weapons in the plant's disease resistance strategy. Researchers at the University of Missouri recently "tapped" into two proteins' communications with the nucleus and discovered a previously unknown level of cross talk. The discovery adds important new information about how plant proteins mediate resistance to bacteria that cause disease and may ultimately lead to novel strategies for ...
Some kids with spinal cord injury may be overlooked for walking rehabilitation
2010-11-16
The traditional way to predict whether children can regain movement after spinal cord injuries may exclude a small subset of patients who could benefit from therapy, according to two studies presented by University of Florida researchers at the Society for Neuroscience meeting this week in San Diego.
In one study, researchers present details of a child with incomplete spinal cord injury who continues to improve four years after recovering walking ability in a locomotor training program at UF, even though clinical assessment tools predicted he would never walk again.
In ...
Rational family structure dominates
2010-11-16
Couples do not live together for traditional or romantic reasons. They do so for purely rational reasons - emotional, financial, intellectual and social. The nuclear family still holds a strong position in Sweden. Some 70 percent of the population live in a nuclear family, shows research from the University of Gothenburg, Sweden.
Many families today consist of networks of various people that include a whole host of constellations, without being a nuclear family.
Family researchers are at any rate pleased at the break up of the nuclear family, and the late 20th century ...
Radiation fears should not deter women from mammography screening
2010-11-16
OAK BROOK, Ill. – The risk of radiation-induced breast cancer from mammography screening is slight in comparison to the benefit of expected lives saved, according to a new study appearing online and in the January issue of the journal Radiology.
"Recently, there have been reports in the press focusing on the potential radiation risk from mammography, particularly as used for periodic screening," said the study's lead author, Martin J. Yaffe, Ph.D., senior scientist in imaging research at Sunnybrook Health Sciences Centre, and professor in the departments of medical biophysics ...
LAST 30 PRESS RELEASES:
Insulin resistance is linked to over 30 diseases – and to early death in women, study of people in the UK finds
Innovative semaglutide hydrogel could reduce diabetes shots to once a month
Weight loss could reduce the risk of severe infections in people with diabetes, UK research suggests
Long-term exposure to air pollution and a lack of green space increases the risk of hospitalization for respiratory conditions
Better cardiovascular health in early pregnancy may offset high genetic risk
Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data releases at IASLC 2024 World Conference on Lung Cancer
Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer
IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer biomarker testing
Research shows pathway to developing predictive biomarkers for immune checkpoint inhibitors
Just how dangerous is Great Salt Lake dust? New research looks for clues
Maroulas appointed Associate Vice Chancellor, Director of AI Tennessee
New chickadee research finds cognitive skills impact lifespan
Cognitive behavioral therapy enhances brain circuits to relieve depression
Terasaki Institute awarded $2.3 Million grant from NIH for organ transplantation research using organs-on-a-chip technology
Atoms on the edge
Postdoc takes multipronged approach to muon detection
Mathematical proof: Five satellites needed for precise navigation
Scalable, multi-functional device lays groundwork for advanced quantum applications
Falling for financial scams? It may signal early Alzheimer’s disease
Integrating MRI and OCT for new insights into brain microstructure
Designing a normative neuroimaging library to support diagnosis of traumatic brain injury
Department of Energy announces $68 million in funding for artificial intelligence for scientific research
DOE, ORNL announce opportunity to define future of high-performance computing
Molecular simulations, supercomputing lead to energy-saving biomaterials breakthrough
Low-impact yoga and exercise found to help older women manage urinary incontinence
Genetic studies reveal new insights into cognitive impairment in schizophrenia
Researcher develops technology to provide cleaner energy and cleaner water
Expect the unexpected: nanoscale silver unveils intrinsic self-healing abilities
nTIDE September 2024 Jobs Report: Gains in employment for people with disabilities appear to level off after reducing gaps with non-disabled workers
Wiley enhances NMR Spectral Library Collection with extensive new databases
[Press-News.org] Erythropoietin counteracts breast cancer treatment with herceptinResearchers find erythropoiesis-stimulating drugs cut response to HER2 targeted therapy